Will a new hope with an advanced drug for the treatment of stage 4 metastatic pancreatic cancer patients prove itself in a new study that has just begun?
The drug is called CPI-613 or Devimistat, and it attacks enzymes involved in the cell’s energy production mechanism. If the cell cannot produce energy, it will die.In a new study that has just begun, the inclusion of CPI-613 is considered standard treatment for these patients and plans to recruit 500 patients.
For further reading
https://www.drugdevelopment-technology.com/…/rafael-launch…/
To find out if you are suitable for this study or for other advanced drugs to treat metastatic pancreatic cancer, contact us and we will be happy to help.
